This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. If the Commonwealth of Massachusetts is a canary in the coal mine for the shape of the U.S. biotech industry, then hold onto your hats. Long home to some of the most concentrated and prolific hubs of biotech R&D, Massachusetts is witnessing a painful downturn in pipeline growth, venture funding, federal support and sector employment, according to a report from indust ...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) is an interesting case. In recent times, the stock price has been under a lot of scrutiny from the unwanted results of some of its clinical trials. Over the past year, the stockI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation ...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) is an interesting case. In recent times, the stock price has been under a lot of scrutiny from the unwanted results of some of its clinical trials. Over the past year, the stockI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.This week, Sarepta will present data from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD).Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program and a real-world evidence study of pulmonary function in advanced-stage patients with Duchenne muscular dystrophy treated with ca ...

We recently published 10 Stocks With Double-Digit Upsides. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top performers on Thursday. Sarepta Therapeutics extended its winning streak to a 5th consecutive day on Thursday, surging 15.68 percent to close at $22.35 apiece as investors repositioned portfolios ahead of the upcoming preliminary results for a drug clinical trial to treat myotonic dystrophy type 1 (DM1). Earlier this year, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said that it would announ ...

Group 1 - The article highlights the challenges faced by Sarepta Therapeutics, Inc. in 2025, indicating it has been a particularly difficult year for the company [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [2] - The group provides detailed financial analyses, including product sales forecasts and integrated financial statements for major pharmaceutical companies [2]

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria. Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study of pulmonary function in advanced-stage patients with. ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Sarepta Therapeutics, Inc. related to the misrepresentation of safety risks associated with the ELEVIDYS treatment [1] Group 1: Allegations Against Sarepta Therapeutics - Insiders at Sarepta Therapeutics allegedly caused the company to misrepresent or fail to disclose significant safety risks posed by the ELEVIDYS treatment [1] - The trial regimes and protocols for ELEVIDYS reportedly failed to detect severe side effects, leading to concerns about patient safety [1] - The severity of adverse events from ELEVIDYS treatment may result in the company halting recruitment and dosing in trials, attracting regulatory scrutiny, and increasing risks around the therapy's approvals [1] - Insiders are accused of materially misleading stakeholders and lacking a reasonable basis for their positive statements regarding ELEVIDYS [1]

Analyst Upgrades and Downgrades - Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc. from Equal-Weight to Overweight, raising the price target from $17 to $25, with shares closing at $20.54 [3] - UBS analyst Alex Kramm upgraded FactSet Research Systems Inc. from Neutral to Buy but lowered the price target from $480 to $425, with shares closing at $289.15 [3] - BMO Capital analyst Kostas Biliouris upgraded Sarepta Therapeutics, Inc. from Market Perform to Outperform, maintaining the price target at $50, with shares closing at $17.43 [3] - Evercore ISI Group analyst Daniel Markowitz upgraded Repligen Corporation from In-Line to Outperform, raising the price target from $130 to $155, with shares closing at $122.30 [3] - Wells Fargo analyst Zachary Fadem upgraded Brinker International, Inc. from Equal-Weight to Overweight, boosting the price target from $165 to $175, with shares closing at $136.35 [3]

Market Performance - Major US stock indices closed lower due to weak non-farm employment data, reinforcing expectations for a Federal Reserve rate cut [1][2] - The Dow Jones Industrial Average fell by 0.48% to 45400.86 points, the S&P 500 decreased by 0.32% to 6481.5 points, and the Nasdaq dropped by 0.03% to 21700.39 points [1] - European indices also closed down, with Germany's DAX down 0.73%, France's CAC40 down 0.31%, and the UK's FTSE 100 down 0.09% [1] Employment Data - The US added only 22,000 jobs in August, significantly below the expected 75,000, with an unemployment rate of 4.3%, marking a 0.1 percentage point increase for the second consecutive month [2] - Job growth was primarily in the healthcare sector, which added 31,000 positions, while manufacturing, wholesale trade, and government sectors saw losses of over 10,000 jobs each [2] - Analysts suggest that tariff policy uncertainties are a major factor contributing to the labor market's weakness [2] Gold Market - International gold prices reached a new high, with COMEX gold futures rising by 0.92% to $3639.8 per ounce [3] - In August, gold ETFs saw a net inflow of $5.5 billion, mainly from North America ($4.1 billion) and Europe ($1.9 billion) [3] - The price of gold has increased by 31% year-to-date, driven by a weak dollar, geopolitical tensions, and continued inflows into gold ETFs [3] Oil Market - US oil prices fell sharply, with the main contract down 2.38% to $61.97 per barrel, and Brent crude down 2.06% to $65.61 per barrel [4][5] - The decline in oil prices is attributed to rising expectations of increased production from OPEC+ and concerns over economic recession [5][6] - OPEC+ is considering further increasing oil production to regain market share, having already raised output by approximately 2.5 million barrels per day since April [6]